• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results

    7/11/24 4:01:00 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $NBIX alert in real time by email

    Conference Call and Webcast Scheduled for Thursday, August 1

    SAN DIEGO, July 11, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it has scheduled its second quarter 2024 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on August 1, 2024.

    (PRNewsfoto/Neurocrine Biosciences, Inc.)

    The schedule for the press release and conference call / webcast is as follows:

    •

    Q2 2024 Press Release:   

    August 1, 2024 at 4:00 a.m. PT / 7:00 a.m. ET

    •

    Q2 2024 Conference Call:         

    August 1, 2024 at 5:00 a.m. PT / 8:00 a.m. ET

    •

    Domestic Dial-In Number:       

    800-445-7795

    •

    International Dial-In Number:   

    785-424-1699

    •

    Conference ID:               

    NBIX

    The webcast can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

    About Neurocrine Biosciences

    Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X (Formerly Twitter) and Facebook. (*in collaboration with AbbVie)

    NEUROCRINE BIOSCIENCES, NEUROCRINE, and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc. The Neurocrine logo is a trademark of Neurocrine Biosciences, Inc.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2024-financial-results-302194771.html

    SOURCE Neurocrine Biosciences, Inc.

    Get the next $NBIX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NBIX

    DatePrice TargetRatingAnalyst
    4/15/2025$138.00Hold → Buy
    Needham
    4/14/2025$137.00Sector Perform → Outperform
    RBC Capital Mkts
    2/11/2025$138.00Hold
    Deutsche Bank
    10/10/2024$155.00Outperform
    Raymond James
    8/29/2024$131.00 → $159.00Neutral → Overweight
    Piper Sandler
    4/24/2024$140.00 → $170.00Equal Weight → Overweight
    Wells Fargo
    12/13/2023$127.00Neutral
    Citigroup
    12/12/2023$136.00Buy
    Deutsche Bank
    More analyst ratings